Ubrogepant: First Approval

Overview

Journal Drugs

Specialty Pharmacology

Date 2020 Feb 6

PMID 32020557

Citations 21

Authors

Lesley J Scott

Affiliations

Soon will be listed here.

Abstract

Ubrogepant (Ubrelvy™) is an orally administered, small molecule, highly-selective, calcitonin gene-related peptide (CGRP) antagonist that was developed by Allergan under license to Merck & Co. as an acute treatment for migraine. In December 2019, ubrogepant received its first global approval in the USA for the acute treatment of migraine (± aura) in adults. This article summarizes the milestones in the development of ubrogepant leading to its first global approval for the acute treatment of migraine (± aura) in adults.

Citing Articles

CGRP promotes osteogenic differentiation by regulating macrophage M2 polarization through HDAC6/AKAP12 signaling pathway.

Chen W, Ma L, Sun W, Xiao W, Guo H, Xiu J Regen Med. 2024; 19(7-8):379-391.

PMID: 39072399 PMC: 11370908. DOI: 10.1080/17460751.2024.2370697.

Migraine and Its Treatment from the Medicinal Chemistry Perspective.

Pehlivanlar E, Carradori S, Simsek R ACS Pharmacol Transl Sci. 2024; 7(4):951-966.

PMID: 38633587 PMC: 11020076. DOI: 10.1021/acsptsci.3c00370.

Comparison of effectiveness and safety of lasmiditan and CGRP-antagonists for the acute treatment of migraine in adults: systematic review and network meta-analysis of randomised trials.

Deng X, Zhou L, Liang C, Shang X, Hui X, Liu W J Headache Pain. 2024; 25(1):16.

PMID: 38311738 PMC: 10840250. DOI: 10.1186/s10194-024-01723-4.

A Comprehensive Review of the Mechanism, Efficacy, Safety, and Tolerability of Ubrogepant in the Treatment of Migraine.

Dighriri I, Nazel S, Alharthi A, Altowairqi N, Albariqi A, Tohari M Cureus. 2023; 15(11):e48160.

PMID: 38046695 PMC: 10693258. DOI: 10.7759/cureus.48160.

Consensus-Based Recommendations on the Use of CGRP-Based Therapies for Migraine Prevention in the UAE.

Alsaadi T, Kayed D, Al-Madani A, Hassan A, Terruzzi A, Krieger D Neurol Ther. 2023; 12(6):1845-1865.

PMID: 37792218 PMC: 10630270. DOI: 10.1007/s40120-023-00550-0.

References

Lipton R, Dodick D, Ailani J, Lu K, Finnegan M, Szegedi A . Effect of Ubrogepant vs Placebo on Pain and the Most Bothersome Associated Symptom in the Acute Treatment of Migraine: The ACHIEVE II Randomized Clinical Trial. JAMA. 2019; 322(19):1887-1898. PMC: 6865323. DOI: 10.1001/jama.2019.16711. View

Ankrom W, Bondiskey P, Li C, Palcza J, Liu W, Dockendorf M . Ubrogepant Is Not Associated With Clinically Meaningful Elevations of Alanine Aminotransferase in Healthy Adult Males. Clin Transl Sci. 2020; 13(3):462-472. PMC: 7214647. DOI: 10.1111/cts.12728. View

Goadsby P, Tepper S, Watkins P, Ayele G, Miceli R, Butler M . Safety and tolerability of ubrogepant following intermittent, high-frequency dosing: Randomized, placebo-controlled trial in healthy adults. Cephalalgia. 2019; 39(14):1753-1761. PMC: 6900570. DOI: 10.1177/0333102419869918. View

Voss T, Lipton R, Dodick D, Dupre N, Ge J, Bachman R . A phase IIb randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraine. Cephalalgia. 2016; 36(9):887-98. DOI: 10.1177/0333102416653233. View

Ailani J, Lipton R, Hutchinson S, Knievel K, Lu K, Butler M . Long-Term Safety Evaluation of Ubrogepant for the Acute Treatment of Migraine: Phase 3, Randomized, 52-Week Extension Trial. Headache. 2020; 60(1):141-152. PMC: 7004213. DOI: 10.1111/head.13682. View

Li C, Voss T, Kowalski K, Yang B, Kleijn H, Jones C . Making Better Dose Decisions: Using Exposure-Response Modeling to Integrate Efficacy Outcome of Two Phase IIb Clinical Trials of Ubrogepant for Migraine Treatment. Clin Transl Sci. 2019; 13(3):482-490. PMC: 7214662. DOI: 10.1111/cts.12730. View

Rubio-Beltran E, Chan K, Danser A, MaassenVanDenBrink A, Edvinsson L . Characterisation of the calcitonin gene-related peptide receptor antagonists ubrogepant and atogepant in human isolated coronary, cerebral and middle meningeal arteries. Cephalalgia. 2019; 40(4):357-366. DOI: 10.1177/0333102419884943. View

Chan C, Goadsby P . Recent Advances in Pharmacotherapy for Episodic Migraine. CNS Drugs. 2019; 33(11):1053-1071. DOI: 10.1007/s40263-019-00665-9. View

Holland P, Goadsby P . Targeted CGRP Small Molecule Antagonists for Acute Migraine Therapy. Neurotherapeutics. 2018; 15(2):304-312. PMC: 5935646. DOI: 10.1007/s13311-018-0617-4. View

10.

Jakate A, Boinpally R, Butler M, Lu K, McGeeney D, Periclou A . Single Therapeutic and Supratherapeutic Doses of Ubrogepant Do Not Affect Cardiac Repolarization in Healthy Adults: Results From a Randomized Trial. Clin Pharmacol Ther. 2019; 107(4):1014-1022. PMC: 7158215. DOI: 10.1002/cpt.1696. View

11.

Dodick D, Lipton R, Ailani J, Lu K, Finnegan M, Trugman J . Ubrogepant for the Treatment of Migraine. N Engl J Med. 2019; 381(23):2230-2241. DOI: 10.1056/NEJMoa1813049. View

12.

Edvinsson L, Haanes K, Warfvinge K, Krause D . CGRP as the target of new migraine therapies - successful translation from bench to clinic. Nat Rev Neurol. 2018; 14(6):338-350. DOI: 10.1038/s41582-018-0003-1. View